Dr Reddy's Laboratories Q4 2024 GAAP EPS ₹78.35 Beats ₹67.78 Estimate, Sales ₹70.830B Miss ₹70.911B Estimate
Portfolio Pulse from Benzinga Newsdesk
Dr Reddy's Laboratories reported a Q4 2024 GAAP EPS of ₹78.35, surpassing the ₹67.78 estimate. However, their sales of ₹70.830 billion fell slightly short of the ₹70.911 billion estimate.
May 07, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Dr Reddy's Laboratories exceeded EPS estimates but missed sales forecasts in Q4 2024.
The mixed results with an EPS beat and a slight miss on sales forecasts could lead to neutral market reactions. Investors might appreciate the earnings strength but be slightly concerned about the sales miss, balancing the stock's short-term outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100